IV. 結核化学療法の現時点での問題点

DOI Web Site PubMed

書誌事項

タイトル別名
  • IV. SEVERAL PROBLEMS RELATING TO THE CHEMOTHERAPY FOR TUBERCULOSIS AT PRESENT
  • ケッカク カガク リョウホウ ノ キジテン デ ノ モンダイテン ダイ 52カ

この論文をさがす

抄録

In this paper, several aspects in the problem of recent status of tuberculosis chemotherapy are discussed in some detail.<BR>There seems to be some difference in the ranking of antituberculous drugs between the IUAT Committee and our group in Japan, especially in the evaluation of pyrazinamide (PZA) and ethambutol. As it might be partly caused by relatively low estimation about the intracellular activity of PZA, further investigations both in laboratory and in clinic are requested.<BR>Intensification of the chemotherapeutic regimen of tuberculosis is realized by the combi nation of bactericidal drugs with careful consideration for the adverse reactions. The outstanding bactericidal activity of rifampicin in vitro was shown by using the silicone-coated slide culture method in the author's laboratory.<BR>As the clinical effect of short-course regimens in tuberculosis chemotherapy is still under investigation, the importance of the observation about the adverse reactions during the treat ment, follow-up of cases dropped out from intensive regimens and 5-years' cumulative relapse rate after the cessation of treatment was strongly pointed out from the author's clinical experiences.<BR>As for the new antituberculous drug developed recently in Japan, enviomycin (EVM), a basic peptide antibiotic, the cross-resistance with KM, CPM and VM should be evaluated precisely.<BR>In vitro results of our experiment and clinical trend about the development of acquired resistance to EVM in our group-study were presented.

収録刊行物

  • 結核

    結核 52 (11), 595-601, 1977

    一般社団法人 日本結核病学会

詳細情報 詳細情報について

問題の指摘

ページトップへ